tasimelteon (Hetlioz®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of Non-24-Hour sleep/wake disorder

Patients must meet the following criteria for the indications above:

  • Patients must be blind
  • The drug is not approved for any use not mentioned above

Dosing:

  • The dose is 20 mg at bedtime
  • Patient must take at the same time each night

Approval:

One year


  

Last review date: May 5, 2014